please help improve it or discuss these issues on the talk page . learn how and when to remove these template messages the topic of this article may not meet wikipedia s notability guidelines for companies and organizations . please help to establish notability by citing reliable secondary sources that are independent of the topic and provide significant coverage of it beyond its mere trivial mention . if notability can not be established the article is likely to be merged redirected or deleted . find sources transgene sa news newspapers books scholar jstor free images may 2013 learn how and when to remove this template message this article needs additional citations for verification . please help improve this article by adding citations to reliable sources . unsourced material may be challenged and removed . may 2013 learn how and when to remove this template message learn how and when to remove this template message type soci t anonyme traded as tng.pa industry biotechnology pharmaceutical founded 1979 headquarters illkirch strasbourg france key people dr. philippe archinard chairman & ceo st phane boissel evp & cfo products tg4010 ; jx594 tg6006 ; tg4040 ; tg4001 website www.transgene.fr transgene sa is a france based fully integrated biopharmaceutical company specialising in immunotherapeutics to treat cancer and infectious diseases . 1 the company has subsidiaries in china and in the usa . the company has been strongly supported by the m rieux family since 1994 . transgene was listed on the paris stock exchange in 1998 . 2 contents 1 history 2 technology 3 clinical products 4 manufacturing 5 notes history edit transgene was founded in 1979 on the initiative of pierre chambon and philippe kourilsky . jean pierre lecocq was the first scientific director of transgene in 1980 . technology edit the core of transgene s discovery platform is gene transfer . this process requires vectors to deliver genes to the target cells . transgene uses three types of vectors modified vaccinia ankara mva ; vaccinia virus and adenovirus . clinical products edit tg4010 a specific active immunotherapy to treat muc1 expressing solid tumors is currently being tested in non small cell lung cancer nsclc in phase iib clinical trials . 3 4 the therapy is based on a recombinant vaccinia virus expressing the muc1 antigen and the human cytokine interleukin 2 il2 . jx594 tg6006 pexa vec is being tested in hepatocellular carcinoma hcc and is currently in phase ii trials . 5 the engineered oncolytic vaccinia virus is armed with the immunostimulatory cytokine gm csf and is designed to selectively target and destroy cancer cells through three diverse mechanisms of action lysis of cancer cells through viral replication the reduction of the blood supply to tumors through vascular targeting and disruption and the stimulation of the body s immune response against cancer cells . 6 results from a phase ii trial have been published in a february 2013 nature medicine article randomized dose finding clinical trial of oncolytic immunotherapeutic vaccinia jx 594 in liver cancer . the peer reviewed article argued that jx 594 demonstrated oncolytic and immunotherapy moa tumor responses and dose related survival in individuals with hcc . 7 in infectious diseases transgene is developing tg4040 an immunotherapy product that is in phase ii clinical trials for the treatment of chronic hepatitis c infections hcv ; 8 and tg4001 which has completed phase ii clinical trails to treat human papilloma virus related infections is also in development with the european organisation for research and treatment of cancer eortc in a phase iib trial to treat head and neck cancer specifically oropharyngeal squamous cell carcinomas . 9 in 2011 partner roche terminated the 2007 agreement under which transgene granted roche exclusive global development and commercialization rights to the therapeutic vaccine . 10 manufacturing edit transgene has a biomanufacturing site that is used for the production and control of starting material for pharmaceutical and clinical development . 11 notes edit http investing.businessweek.com research stocks snapshot snapshot.asp ticker tng fp http www.lyonbiopole.com exchange entreprise 56 transgene sa.html http clinicaltrials.gov show nct01383148 http www.thelancet.com journals lanonc article piis1470 2045 % 2811 % 2970259 5 fulltext http clinicaltrials.gov ct2 results term jx594 http www.thelancet.com journals lanonc article piis1470 2045 % 2808 % 2970107 4 fulltext jx 594 demonstrated oncolytic and immunotherapy moa tumor responses and dose related survival in individuals with hcc . nature medicine 19 329 336 2013 doi 10.1038 nm .3089 http clinicaltrials.gov ct2 show nct01055821 term tg4040 & rank 2 http www.eortc.org fuzzysearch results transgene % 20sa http informahealthcare.com doi abs 10.1517 13543776.2012.673589 http www.emrreports.com english reports transgene sa tng financial and strategic swot analysis review2.html retrieved from https en.wikipedia.org w index.php title transgene sa & oldid 703368127 categories biotechnology companies of francecompanies established in 1979hidden categories articles with topics of unclear notability from may 2013all articles with topics of unclear notabilityarticles needing additional references from may 2013all articles needing additional references navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page print export create a bookdownload as pdfprintable version languages fran ais edit links this page was last modified on 5 february 2016 at 02 33 . text is available under the creative commons attribution sharealike license ; additional terms may apply . by using this site you agree to the terms of use and privacy policy . wikipedia is a registered trademark of the wikimedia foundation inc. a non profit organization . privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view